Recent Quotes (30 days)

You have no recent quotes
chg | %

Easton Pharmaceuticals Inc  

(Public, OTCMKTS:EAPH)   Watch this stock  
Find more results for EAPH
-0.00036 (-6.00%)
Oct 9 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.01 - 0.04
Open 0.01
Vol / Avg. 574,909.00/1.02M
Mkt cap 3.27M
P/E     -
Div/yield     -
EPS 0.00
Shares 224.71M
Beta -10.69
Inst. own     -

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.35% -29.33%
Return on average equity -239.86% -132.63%
Employees 5 -
CDP Score - -


Suite 500, 425 University Ave.
+1-416-6190291 (Phone)
+1-416-6461000 (Fax)

Website links


Easton Pharmaceuticals Inc., formerly LAM Industries, Inc, develops, markets and licenses wound healing and transdermally delivered drugs, therapeutic preparations and cosmetics for the prescription, over-the-counter and cosmetic markets, using its L.A.M. Ionic Polymer Matrix technology (L.A.M. IPM). The Company has one commercially available product, the L.A.M. IPM Wound Gel, a hydrogel used for wound healing. The L.A.M. IPM Wound Gel received approval from the United States Food and Drug Administration in April 2002, and was launched by L.A.M. in August 2002. All other potential products of the Company, which includes Post Surgical Matrix, Burn Matrix and products for female sexual dysfunction and dry skin, are in various stages of development and testing. In December 2009, the Company announced the acquisitions of Viorra Bio Medical Inc. and Ixora Bio Medical Company Inc.

Officers and directors

John Adams President, Chief Executive Officer
Age: 53
Walter Folinski Chief Financial Officer
Neil Mellor Chief Operating Officer
Jack Barkin M.D. Senior Vice President, Chief Medical Officer
Susan Whyte Vice President - Marketing
John Mitchell Vice President - Business Development